Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemziviptadil - PhaseBio Pharmaceuticals

Drug Profile

Pemziviptadil - PhaseBio Pharmaceuticals

Alternative Names: PB 1046; Vasomera

Latest Information Update: 03 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antihypertensives; Cardiovascular therapies; Heart failure therapies; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Pulmonary arterial hypertension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiomyopathies; Heart failure; Pulmonary arterial hypertension; SARS-CoV-2 acute respiratory disease
  • No development reported Cystic fibrosis; Essential hypertension

Most Recent Events

  • 04 Feb 2022 PhaseBio Pharmaceuticals terminates a phase II long-term extension trial for Pulmonary arterial hypertension in USA (NCT03795428)
  • 21 Dec 2021 PhaseBio Pharmaceuticals suspends a phase II long-term extension trial for Pulmonary arterial hypertension in USA (NCT03795428)
  • 21 Dec 2021 PhaseBio Pharmaceuticals terminates a phase II trial in Pulmonary arterial hypertension in USA, Spain, Hungary, Poland, Greece, Bulgaria and Austria (SC) due to COVID-19 impacts, associated drug supply and the rate of enrolment (NCT03556020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top